A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen (NasdaqGS:AMGN) released Phase 3 data for a subcutaneous, on-body injector version of TEPEZZA for Thyroid Eye Disease.

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited ...

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

Amgen followed up on Viridian Therapeutics' sizable crash Monday, delivering positive results for its next-generation Tepezza.

Amgen AMGN announced positive top-line results from a late-stage study evaluating the subcutaneous (under the skin or SC) ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...